Friday, 20 Sep 2019

You are here

NIH Workshop on Unmet Needs in Osteoporosis

In October 2018, the National Institutes of Health (NIH) convened a workshop to address the "Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention"

They specifically examined the evidence on long-term (>3 years) use to prevent osteoporotic fractures and identify research gaps and needs for advancing the field.  The Annals of Internal Medicine has published the final report summarizing the panel's recommendations. 

The report reviews that and estimated that 8 million adult women and 2 million men have osteoporosis (8), and 27 million women and 16 million men have low bone mass. Moreover by 2025, it is estimated that the U.S. health care costs attributable to OP fractures will reach $25 billion annually.

While there are many FDA approved pharmacologic treatments that may prevent fractures, it is estimated that many at high fracture risk remain untreated. One study has shown that less than 20% of women received osteoporosis treatment in the year after diagnosis of an initial fragility fracture. 

Highlights from the workshop include:

  1. Need for new trials and new trial designs - in addition to fracture outcomes, more data is needed on patient morbidity and survival, sequelae of fractures, functional status, mobility, hospitalizations, etc. 
  2. More data on rare events such as atypical femoral fractures (AFFs) and osteonecrosis of the jaw (ONJ). Data from observational studies and postmarketing surveillance suggests that the age-adjusted incidence rates for AFFs is 1.78 per 100 000 person-years (95% CI, 1.5 to 2.0 per 100 000 person-years) with bisphosphonate exposure of 0.1 to 1.9 years, and increased to 113.1 per 100 000 person-years (CI, 69.3 to 156.8 per 100 000 persons per year) with bisphosphonate exposure of 8 to 9.9 years (16). For ONJ, the incidence is 1 to 69 per 100 000 patient-years with oral bisphosphonates and 0 to 90 per 100 000 patient-years with intravenous bisphosphonates. These incidence rates are marginally higher than those of the general patient population.
  3. Drug Holidays: there are knowleged gaps on the the long-term effects of “drug holidays,” especially for bisphosphonates. 
  4. More research on barriers to treating osteoporosis.
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Need for Pre-operative Hyperglycemia Testing Prior to Total Joint Replacement

JAMA reports on a large Medicare cohort study showing that amongst patients undergoing total joint replacement (TJR), preoperative HbA1c testing was performed in 26% to 43% of patients with diabetes and in only 5% of those without diabetes. Importantly research has shown that an elevated HbA1c level is associated with postoperative complications.

Weight Loss Cuts Hospital Stays for Obese TKA Patients

Morbidly obese patients who lost 20 lbs before total knee arthroplasty (TKA) cut their hospital stays by about 1 day, and were 76% less likely to have an extended hospital stay, research showed. 

High-Dose Vitamin D: No Help for Bone Health

Vitamin D might not be much help for strengthening bones among healthy adults without osteoporosis, Canadian researchers reported, even at doses far higher than recommended daily allowances. In a clinical trial assessing three levels of daily vitamin D supplementation -- 400 IU, 4,000 IU, and 10,000 IU -- radial volumetric bone mineral density was significantly lower among those (ages 55-70) taking higher doses for 3 years, according to Steven Boyd, PhD, of the University of Calgary in Canada, and colleagues.

Osteoporosis Tx: Good for Bones, but Not for Cutting Death Risk

Osteoporosis treatments were not linked with reduced overall mortality, according to a meta-analysis of placebo-controlled trial data.

Looking at data from 38 clinical trials, there was no significant association found between all drug-based osteoporosis treatments and overall mortality rate (risk ratio 0.98, 95% CI 0.91-1.05), reported Steven Cummings, MD, of the San Francisco Coordinating Center, and colleagues.

Bisphosphonate Use Associated with Reduced Mortality

The Journal of Bone and Mineral Research (JBMR) has published a report showing that a reduction in the rate of bone loss by nitrogen bisphosphonates was associated with a 40% lower mortality risk.

Accelerated bone loss has been shown to be an independent predictor of mortality risk, but the relationship between bisphosphonates, bone loss, and mortality is unknown.